CR20210045A - Inhibidores de inflamasoma nlrp3 - Google Patents
Inhibidores de inflamasoma nlrp3Info
- Publication number
- CR20210045A CR20210045A CR20210045A CR20210045A CR20210045A CR 20210045 A CR20210045 A CR 20210045A CR 20210045 A CR20210045 A CR 20210045A CR 20210045 A CR20210045 A CR 20210045A CR 20210045 A CR20210045 A CR 20210045A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- nlrp3
- nlrp3 inflammasome
- inflammasome inhibitors
- inhibitors
- Prior art date
Links
- 229940122390 Inflammasome inhibitor Drugs 0.000 title 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 title 1
- 108010034143 Inflammasomes Proteins 0.000 abstract 1
- 102000012064 NLR Proteins Human genes 0.000 abstract 1
- 108091005686 NOD-like receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a nuevos compuestos de tienopirrolotriazinacetamida de la fórmula (I): (I), en donde R1, R2 y R3 se definen en el presente documento, 5 que inhiben la actividad inflamatoria de la proteína 3 receptora de tipo NOD (NLRP3). La invención se refiere, además, a los procesos para su preparación, composiciones farmacéuticas y medicamentos que los contienen, y su uso en el tratamiento de enfermedades y trastornos mediados por NLRP3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18185580 | 2018-07-25 | ||
EP19175246 | 2019-05-17 | ||
PCT/IB2019/056278 WO2020021447A1 (en) | 2018-07-25 | 2019-07-23 | Nlrp3 inflammasome inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210045A true CR20210045A (es) | 2021-06-18 |
Family
ID=67989037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210045A CR20210045A (es) | 2018-07-25 | 2019-07-23 | Inhibidores de inflamasoma nlrp3 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20210308140A1 (es) |
EP (1) | EP3827008A1 (es) |
JP (1) | JP2021532124A (es) |
KR (1) | KR20210038877A (es) |
CN (1) | CN112424207B (es) |
AU (1) | AU2019309727B2 (es) |
BR (1) | BR112021000964A2 (es) |
CA (1) | CA3103943A1 (es) |
CL (1) | CL2021000191A1 (es) |
CO (1) | CO2021000537A2 (es) |
CR (1) | CR20210045A (es) |
CU (1) | CU20210009A7 (es) |
DO (1) | DOP2021000019A (es) |
EC (1) | ECSP21004787A (es) |
IL (1) | IL280336A (es) |
JO (1) | JOP20210017A1 (es) |
MA (1) | MA53388A (es) |
MX (1) | MX2021000925A (es) |
PE (1) | PE20210406A1 (es) |
PH (1) | PH12021550166A1 (es) |
SG (1) | SG11202012321PA (es) |
WO (1) | WO2020021447A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230330054A1 (en) * | 2020-03-31 | 2023-10-19 | Olatec Therapeutics Llc | Method for preventing or treating lung infection and lung inflammation |
MX2022012897A (es) | 2020-04-15 | 2022-11-14 | Janssen Pharmaceutica Nv | Pirazolo[1,5-d][1,2,4]triazin-5(4h)acetamidas como inhibidores de la ruta del inflamasoma nlrp3. |
JP2023521242A (ja) | 2020-04-15 | 2023-05-23 | ヤンセン ファーマシューティカ エヌ.ベー. | NLRP3インフラマソーム経路の阻害剤としてのピロロ[1,2-d][1,2,4]トリアジン-2-イル-アセトアミド |
KR20230005252A (ko) | 2020-04-23 | 2023-01-09 | 얀센 파마슈티카 엔.브이. | Nlrp3의 억제제로서의 삼환식 화합물 |
JP2023523756A (ja) | 2020-04-30 | 2023-06-07 | ヤンセン ファーマシューティカ エヌ.ベー. | 新規なトリアジノインドール化合物 |
AU2021279305A1 (en) | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
WO2021255279A1 (en) | 2020-06-19 | 2021-12-23 | Ac Immune Sa | D i h yd rooxazo le and thiourea derivatives modulating the nlrp3 inflammasome pathway |
EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
WO2022063896A1 (en) | 2020-09-24 | 2022-03-31 | Janssen Pharmaceutica Nv | New compounds |
CN114478537B (zh) * | 2020-11-13 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 环酰胺并环化合物及其医药用途 |
JP2024508010A (ja) | 2021-03-04 | 2024-02-21 | ヤンセン ファーマシューティカ エヌ.ベー. | Nlrp3を調節する4-アミノ-6-オキソ-ピリダジン誘導体 |
MX2023010310A (es) | 2021-03-04 | 2023-09-12 | Janssen Pharmaceutica Nv | Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3. |
CN113230240B (zh) * | 2021-03-22 | 2022-12-27 | 广州医科大学 | 1,3-二苯基丙-2-烯-1-酮衍生物及其应用 |
CA3215235A1 (en) | 2021-04-13 | 2022-10-20 | Sharon KLIER | Methods of treating retinal vasculopathies |
US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
WO2022229315A1 (en) * | 2021-04-29 | 2022-11-03 | Janssen Pharmaceutica Nv | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
CA3166147A1 (en) | 2021-06-23 | 2022-12-23 | Yoda Pharmaceuticals Inc. | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 |
WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
WO2023028536A1 (en) * | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
WO2023044043A1 (en) * | 2021-09-17 | 2023-03-23 | Denali Therapeutics Inc. | Compounds, compositions and methods |
KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
WO2023156643A1 (en) * | 2022-02-21 | 2023-08-24 | Sanofi | Thienopyrrolotriazine compounds, their preparation and their therapeutic use |
US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
WO2024033845A1 (en) * | 2022-08-10 | 2024-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
WO2024064245A1 (en) | 2022-09-23 | 2024-03-28 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009008906A2 (en) * | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
WO2010128152A1 (en) | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
KR20120087950A (ko) | 2009-10-20 | 2012-08-07 | 노파르티스 아게 | 글리코시드 유도체 및 그의 용도 |
UA111272C2 (uk) | 2010-06-23 | 2016-04-11 | Ханмі Сайєнс Ко., Лтд. | Конденсовані піримідинові похідні для інгібування тирозинкіназної активності |
CA2807051A1 (en) | 2010-08-10 | 2012-02-16 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
CA2833771C (en) | 2011-06-10 | 2021-08-03 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
KR102021651B1 (ko) | 2011-11-29 | 2019-09-16 | 오노 야꾸힝 고교 가부시키가이샤 | 퓨리논 유도체 염산염 |
US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
EP2892900B1 (en) | 2012-09-10 | 2017-08-16 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
MX2015006710A (es) | 2012-11-28 | 2016-01-15 | Intercept Pharmaceuticals Inc | Tratamiento de las enfermedades pulmonares. |
UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
TWI662027B (zh) | 2013-11-05 | 2019-06-11 | 諾華公司 | 用於調節泫尼酯(farnesoid)x受體之組合物及方法 |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
AP2016009301A0 (en) | 2013-12-20 | 2016-06-30 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CU24481B1 (es) | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
KR102375396B1 (ko) | 2014-05-13 | 2022-03-18 | 노파르티스 아게 | 연골형성을 유도하기 위한 화합물 및 조성물 |
TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
SI3461821T1 (sl) | 2014-10-24 | 2020-09-30 | Bristol-Myers Squibb Company | Spojine indol karboksamida, uporabne kot kinazni inhibitorji |
AU2015371254B2 (en) | 2014-12-24 | 2021-06-24 | Principia Biopharma Inc. | Site specific dosing of a BTK inhibitor |
PL3303334T3 (pl) | 2015-06-03 | 2021-11-08 | Principia Biopharma Inc. | Inhibitory kinaz tyrozynowych |
US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
RU2018115334A (ru) | 2015-10-09 | 2019-11-11 | Ацея Терапьютикс, Инк. | Фармацевтические соли, физические формы и композиции пирролопиримидиновых ингибиторов киназ, и способы их получения |
JP6913100B2 (ja) | 2015-11-04 | 2021-08-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Btk阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法 |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
ES2875384T3 (es) | 2016-01-05 | 2021-11-10 | Jiangsu Hengrui Medicine Co | Forma cristalina del inhibidor de la quinasa BTK y método de preparación del mismo |
BR112018071347A2 (pt) * | 2016-04-19 | 2019-02-05 | Innate Tumor Immunity Inc | moduladores de nlrp3 |
KR101865120B1 (ko) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | 테스트 노드 기반의 무선 측위 방법 및 그 장치 |
IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
EP3668843A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
-
2019
- 2019-07-23 KR KR1020217001895A patent/KR20210038877A/ko unknown
- 2019-07-23 CU CU2021000009A patent/CU20210009A7/es unknown
- 2019-07-23 MA MA053388A patent/MA53388A/fr unknown
- 2019-07-23 JP JP2021503752A patent/JP2021532124A/ja active Pending
- 2019-07-23 JO JOP/2021/0017A patent/JOP20210017A1/ar unknown
- 2019-07-23 CA CA3103943A patent/CA3103943A1/en active Pending
- 2019-07-23 EP EP19769892.1A patent/EP3827008A1/en active Pending
- 2019-07-23 US US17/259,252 patent/US20210308140A1/en active Pending
- 2019-07-23 AU AU2019309727A patent/AU2019309727B2/en not_active Ceased
- 2019-07-23 BR BR112021000964-7A patent/BR112021000964A2/pt not_active Application Discontinuation
- 2019-07-23 PE PE2021000092A patent/PE20210406A1/es unknown
- 2019-07-23 CR CR20210045A patent/CR20210045A/es unknown
- 2019-07-23 WO PCT/IB2019/056278 patent/WO2020021447A1/en active Application Filing
- 2019-07-23 SG SG11202012321PA patent/SG11202012321PA/en unknown
- 2019-07-23 MX MX2021000925A patent/MX2021000925A/es unknown
- 2019-07-23 CN CN201980047047.4A patent/CN112424207B/zh active Active
-
2021
- 2021-01-21 PH PH12021550166A patent/PH12021550166A1/en unknown
- 2021-01-21 IL IL280336A patent/IL280336A/en unknown
- 2021-01-22 CL CL2021000191A patent/CL2021000191A1/es unknown
- 2021-01-22 CO CONC2021/0000537A patent/CO2021000537A2/es unknown
- 2021-01-22 EC ECSENADI20214787A patent/ECSP21004787A/es unknown
- 2021-01-22 DO DO2021000019A patent/DOP2021000019A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20210308140A1 (en) | 2021-10-07 |
WO2020021447A1 (en) | 2020-01-30 |
JOP20210017A1 (ar) | 2021-01-21 |
CN112424207B (zh) | 2024-03-19 |
CL2021000191A1 (es) | 2021-08-20 |
CN112424207A (zh) | 2021-02-26 |
MA53388A (fr) | 2021-06-02 |
PE20210406A1 (es) | 2021-03-02 |
CA3103943A1 (en) | 2020-01-30 |
ECSP21004787A (es) | 2021-03-31 |
DOP2021000019A (es) | 2021-02-15 |
CU20210009A7 (es) | 2021-08-06 |
JP2021532124A (ja) | 2021-11-25 |
EP3827008A1 (en) | 2021-06-02 |
IL280336A (en) | 2021-03-01 |
SG11202012321PA (en) | 2021-02-25 |
BR112021000964A2 (pt) | 2021-04-20 |
PH12021550166A1 (en) | 2021-09-13 |
AU2019309727A1 (en) | 2021-01-07 |
AU2019309727B2 (en) | 2021-12-23 |
KR20210038877A (ko) | 2021-04-08 |
MX2021000925A (es) | 2021-03-31 |
CO2021000537A2 (es) | 2021-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000925A (es) | Inhibidores de inflamasoma nlrp3. | |
MX2021013941A (es) | Inhibidores del inflamasoma nlrp3. | |
PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
EA202091512A1 (ru) | Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы | |
PH12020550341A1 (en) | Niraparib formulations | |
CR20220031A (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
MX2022006700A (es) | Compuestos poliheterociclicos como inhibidores de mettl3. | |
MX2020010805A (es) | Inhibidores de bcl6. | |
MX2015011353A (es) | N-(4-(azaindazol-6-il)-fenil)-sulfonamidas y su uso como productos farmaceuticos. | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
ZA202104940B (en) | Novel substituted sulfonylurea derivatives | |
MX2014002736A (es) | N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos farmaceuticos. | |
CR20210101A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
WO2023159148A3 (en) | Inhibitors of nlrp3 | |
MX2022013890A (es) | Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos. | |
WO2017168454A3 (en) | Novel compounds as btk inhibitors | |
EA202190329A1 (ru) | Ингибиторы инфламмасомы nlrp3 | |
MX2019014436A (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa. | |
EA202191103A1 (ru) | Терапевтические соединения | |
ZA202306305B (en) | Pharmaceutical compounds |